FDA calls ecstasy a 'breakthrough' drug for PTSD therapy

FDA calls ecstasy a 'breakthrough' drug for PTSD therapy

For those facing the agony, they may soon get to have the ecstasy.

The FDA has designated the drug ecstasy a "breakthrough" in conjunction with psychotherapy for PTSD treatment.

The special status will allow the closely monitored combination of therapy and the drug, clinically known as MDMA, to get through clinical trials faster.

Working with the non-profit Multidisciplinary Association for Psychedelic Studies, two Phase 3 clinical trials of MDMA-assisted psychotherapy are set to take place next year featuring patients suffering from severe PTSD.

According to MAPS, approximately 7% of the U.S. population and 11 to 17% of U.S. military veterans will face PTSD at some point. One out of every four suicides are associated with the condition.

As Popular Science reports, a previous study found that that 67% of patients with PTSD showed no signs of the disease after undergoing just three sessions.

The FDA approved the "breakthrough" status in large part because MDMA-assisted psychotherapy may offer vastly improved results over other treatment methods.

The watchdog agency is currently run by Commissioner Dr. Scott Gottlieb, a Trump appointee.

Just last month, the FDA defied the White House's admiration for uninformed skepticism over science by seeking to bring nicotine levels in cigarettes down to nonaddictive levels, citing the millions of people who die prematurely due to smoking.

What Australia's bad flu season means for Europe, North America

What Australia's bad flu season means for Europe, North America

Trial raises Parkinson's therapy hope

Trial raises Parkinson's therapy hope